Evidence map›Paper›PMID 23238816›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2013

Part II. Mitochondrial mutational status of high nitric oxide adapted cell line BT-20 (BT-20-HNO) as it relates to human primary breast tumors.

H De Vitto, B S Mendonça, K M Elseth, B J Vesper, E A Portari, C V M Gallo, W A Paradise, F D Rumjanek, J A Radosevich

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. NO control of mitochondrial function in normal and transformed cells.Biochimica et biophysica acta. Bioenergetics · 2017
    Review
  3. Article
  4. A549 cells adapted to high nitric oxide show reduced surface CEACAM expression and altered adhesion and migration properties.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Article
  5. Article
  6. Part II-mechanism of adaptation: A549 cells adapt to high concentration of nitric oxide through bypass of cell cycle checkpoints.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
  7. Mitochondrial DNA mutations and breast tumorigenesis.Biochimica et biophysica acta · 2013
    Review
  8. Part I. Molecular and cellular characterization of high nitric oxide-adapted human breast adenocarcinoma cell lines.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

H De VittoUniversidade Federal do Rio de Janeiro, IBqM, Rio de Janeiro, Brazil.
B S Mendonça
K M Elseth
B J Vesper
E A Portari
C V M Gallo
W A Paradise
F D Rumjanek
J A Radosevich
Universidade Federal do Rio de Janeiro · BRJesse Brown VA Medical Center · USUniversity of Illinois Chicago · USFundação Oswaldo Cruz · BRUniversidade do Estado do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitochondria combine hydrogen and oxygen to produce heat and adenosine triphosphate (ATP). As a toxic by-product of oxidative phosphorylation (OXPHOS), mitochondria generate reactive oxygen species (ROS). These free radicals may cause damage to mitochondrial DNA (mtDNA) and other molecules in the cell. Nitric oxide (NO) plays an important role in the biology of human cancers, including breast cancer; however, it is still unclear how NO might affect the mitochondrial genome. The aim of the current study is to determine the role of mtDNA in the breast oncogenic process. Using DNA sequencing, we studied one breast cancer cell line as a model system to investigate the effects of oxidative stress. The BT-20 cell line was fully adapted to increasing concentrations of the NO donor DETA-NONOate and is referred to as BT-20-HNO, a high NO (HNO) cell line. The HNO cell line is biologically different from the "parent" cell line from which it originated. Moreover, we investigated 71 breast cancer biopsies and the corresponding noncancerous breast tissues. The free radical NO was able to generate somatic mtDNA mutations in the BT-20-HNO cell line that were missing in the BT-20 parent cell line. We identified two somatic mutations, A4767G and G13481A, which changed the amino acid residues. Another two point mutations were identified in the mtDNA initiation replication site at nucleotide 57 and at the 'hot spot' cytidine-rich D300-310 segment. Furthermore, the NO regulated the mtDNA copy number and selected different mtDNA populations by clonal expansion. Interestingly, we identified eight somatic mutations in the coding regions of mtDNAs of eight breast cancer patients (8/71, 11.2 %). All of these somatic mutations changed amino acid residues in the highly conserved regions of mtDNA which potentially leads to mitochondrial dysfunctions. The other two somatic mtDNA mutations in the displacement loop (D-loop) region [303:315 C(7-8)TC(6) and nucleotide 57] were distributed among 14 patients (14/71, 19.7 %). Importantly, of these 14 patients, six had mutations in the p53 gene. These results validate the BT-20 parent/HNO cell line model system as a means to study ROS damage in mtDNA, as it parallels the results found in a subset of the patient population.

Indexed as

ActinsAdaptation, PhysiologicalBreast NeoplasmsCell Line, TumorCell ProliferationDNA, MitochondrialDNA, NeoplasmFemaleGene DosageGene Expression Regulation, NeoplasticGenome, MitochondrialHumansMitochondriaMutationNADH DehydrogenaseNitric OxideActinsDNA, MitochondrialDNA, NeoplasmNADH DehydrogenaseNitric OxideReactive Oxygen SpeciesTumor Suppressor Protein p53

Identifiers

PMID23238816
OpenAlexW2146788970

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.